At a glance
ClinicalIndex Comparison Record- ✓Age 12-40 years
- ✓Delivery at Duke Hospital
- ✓Has working telephone number
- ✓No contraindications to etonogestrel implant, including: no known/suspected pregnancy, no active liver disease or hepatic tumor, no history of thrombosis or thromboembolic disorder, no undiagnosed abnormal genital bleeding, no known/suspected or prior breast cancer, no hypersensitivity to device components
- ✕Use of non-nucleoside reverse transcriptase inhibitors (NNRTIs)
- ✕Use of ritonavir-boosted protease inhibitors
- ✕Use of certain anticonvulsants: phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine
- ✕Use of rifampin
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Controlled Trial of Immediate Postpartum Etonogestrel Implant Versus Six-week Postpartum Etonogestrel Implant: A Pilot Study
In Brief
A Phase 4 clinical trial evaluating Etonogestrel implant for Continuation Rate of Contraceptive Implant. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The investigators are examining if there is a difference in continuation rates of the etonogestrel contraceptive implant between women who have the device placed immediately after delivery, before leaving the hospital, and women who have the device placed at the routine 6-week postpartum visit. There will be 60 subjects total, randomized in a 1:1 ratio, for 30 in each group. All participants will follow-up at the same postpartum clinic 6 weeks after delivery. They will then be contacted at 3, 6, and 12 months postpartum and asked to complete a brief survey. The investigators hypothesize that continuation rates of Implanon will be higher in the immediate postpartum placement arm than in the delayed placement arm.
Study Details
Timeline
Interventions
This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.